------------------------------
OMB APPROVAL
------------------------------
OMB Number 3235-0362
Expires: April 30, 1997
Estimated average burden
hours per response ....... 1.0
------------------------------
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 5
ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or
Section 30(f) of the Investment Company Act of 1940
[ ] Check this box if no longer subject of Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).
[ x] Form 3 Holdings Reported
[ x] Form 4 Transactions Reported
==============================================================================
1. Name and Address of Reporting Person
Novartis Inc.
- ------------------------------------------------------------------------------
(Last) (First) (Middle)
Schwarzwaldallee 215
- ------------------------------------------------------------------------------
(Street)
CH-4002 Basel, Switzerland
- ------------------------------------------------------------------------------
(City) (State) (Zip)
==============================================================================
2. Issuer Name and Ticker or Trading Symbol
Chiron Corporation/CHIR
==============================================================================
3. IRS or Social Security Number of Reporting Person (Voluntary)
==============================================================================
4. Statement for Month/Year
1995, 1996
==============================================================================
5. If Amendment, Date of Original (Month/Year)
==============================================================================
6. Relationship of Reporting Person to Issuer
(Check all applicable)
[ ] Director [ X ] 10% Owner
[ ] Officer (give title below) [ ] Other (specify below)
--------------------------------------------------------------------
<PAGE>
==============================================================================
Table I -- Non-Derivative Securities Acquired, Disposed of,
or Beneficially Owned
==============================================================================
<TABLE>
<CAPTION>
5. 6.
4. Amount of Owner-
Security Acquired (A) or Securities ship
Disposed of (D) Beneficially Form: 7.
(Instr. 3, 4 and 5) Owned at End Direct Nature of
2. 3. ----------------------------- of Issuer's (D) or Indirect
1. Transaction Transaction (A) Fiscal Year Indirect Beneficial
Title of Security Date Code Amount or Price (Instr. 3 (I) Ownership
(Instr. 3) (mm/dd/yy) (Instr. 8) (D) & 4) (Instr.4) (Instr. 4)
- --------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Common Stock 3* 5,121,460 I Through
Novartis
Pharma Inc.
- --------------------------------------------------------------------------------------------------------------------------------
Common Stock 3* 47,441,868 I Through
Novartis
Biotech
- --------------------------------------------------------------------------------------------------------------------------------
Common Stock 1/4/95 P/4 26,400,000 A ** 26,400,000 I Through
Novartis
Biotech
- --------------------------------------------------------------------------------------------------------------------------------
Common Stock 5/3/95 P/4 960 A $29.25 960 I Through
Novartis
Biotech
- --------------------------------------------------------------------------------------------------------------------------------
Common Stock 6/2/95 L/4 24 A $29.25 24 I Through
Novartis
Biotech
- --------------------------------------------------------------------------------------------------------------------------------
Common Stock 11/9/95 J/4 7,456 A *** 7,456 I Through
Novartis
Corporation
- --------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
==================================================================================================================================
</TABLE>
Reminder: Report on a separate line for each class of securities beneficially
owned directly or indirectly
<PAGE>
FORM 5 (continued)
Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
================================================================================
<TABLE>
<CAPTION>
9. 10.
Number Owner-
of ship
2. Deriv- of
Conver- 5. 7. ative Deriv- 11.
sion Number of Title and Amount Secur- ative Nature
or Derivative 6. of Underlying 8. ities Secur- of
Exer- Securities Date Securities Price Bene- ity: In-
cise 3. Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct
Price Trans- 4. or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene-
1. of action Trans- of (D) (Month/Day/Year) Amount ative at End In- ficial
Title of Deriv- Date action (Instr. 3, ---------------- or Secur- of direct Owner-
Derivative ative (Month/ Code 4 and 5) Date Expira- Number ity Year (I) ship
Security Secur- Day/ (Instr. ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr.
(Instr. 3) ity Year) 8) (A) (D) cisable Date Title Shares 5) 4) 4) 4)
- ----------------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C> <C>
7-1/4% Convertible
Subordinated Deben- Common
tures due 2015 $47 3* Anytime 7/1/2015 Stock 348,028 $10,069,000 D
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
- ----------------------------------------------------------------------------------------------------------------------------------
==================================================================================================================================
Explanation of Responses:
* Novartis Inc., the successor by consolidation to Ciba-Geigy Limited and Sandoz Ltd., became the beneficial owner of in excess
of 10% of the outstanding common shares of Chiron Corporation ("Chiron") through a public tender offer by its indirect wholly
owned subsidiary, Novartis Biotech Partnership, Inc. (formerly Ciba Biotech Partnership, Inc.), that expired on January 3, 1995.
Novartis Inc. owned 5,121,460 shares of common stock and $10,069,000 of 7-1/4% Convertible Subordinated Debentures as of such date.
** Acquired in exchange for all the outstanding capital stock of Ciba Corning Diagnostics Corp. and Ciba-Geigy Biocine Corpora-
tion, 50% of the equity in JV Vax, B.V. and all right, title and interest of Novartis Inc. in any intangible assets held for the
benefit of such entities by Novartis Inc. and its subsidiaries.
*** Securities received as a distribution from Accel IV L.P.
All information reflects a 4-for-1 stock split.
</TABLE>
/s/ Urs Barlocher
/a/ Martin Henrich January 17, 1997
- --------------------------------------------- -----------------------
**Signature of Reporting Person Date
** Intentional misstatements or omissions of facts constitute Federal Criminal
Violations.
See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.
Potential persons who are to respond to the collection of information
contained in this form are not required to respond unless the form displays
a currently valid OMB number.
